Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Adipose-derived stem cells attenuate rheumatoid arthritis by restoring CX 3 CR1 + synovial lining macrophage barrier.

Wang L., Hao M., Xu Y., Wang Z., Xie H., Zhang B.

Animal Study on Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40038808
PMCID
PMC11881422
DOI
10.1186/s13287-025-04144-5
Citations
8

Abstract (original English)

Background Rheumatoid arthritis (RA) is a chronic autoimmune disease and the integrity of CX 3 CR1 + synovial macrophage barrier significantly impacts its progression. However, the mechanisms driving the dynamic changes of this macrophage barrier remain unclear. Traditional drug therapies for RA have substantial limitations. Mesenchymal stem cells (MSCs)-based cell therapy, especially adipose-derived stem cells (ADSCs), hold therapeutic promise. Nevertheless, the underlying therapeutic mechanism of ADSCs, especially their interactions with CX 3 CR1 + macrophages, require further investigation. Methods To explore the interaction between ADSCs and CX 3 CR1 + synovial macrophages during barrier reconstruction, underlying the therapeutic mechanism of ADSCs and the mechanisms on the dynamic changes of the macrophage barrier, scRNA-seq analysis was conducted 4 days after ADSCs injection in serum transfer-induced arthritis model mice. The roles of mitochondria transfer and ADSCs transplantation were also explored. Bulk RNA-seq analysis was performed after the co-culture of ADSCs and CX 3 CR1 + synovial macrophages. To study the in vivo fate of ADSCs, bulk RNA-seq was performed on ADSCs retrieved at 0, 2, 4, and 7 days post-injection. Results Intra-articular injection of ADSCs effectively attenuated the pathological progression of mice with serum transfer-induced arthritis. ADSCs gradu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsArthritis, RheumatoidCX3C Chemokine Receptor 1MiceMacrophagesAdipose TissueMesenchymal Stem CellsSynovial MembraneMaleMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research